Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20
What Is The Predicted Market Size Trajectory For The Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market From 2025 To 2034?
The market for ribonucleic acid (RNA)-based oncolytic therapy has experienced swift expansion in recent years. This market is projected to expand from $1.78 billion in 2024 to $2.12 billion in 2025, demonstrating a compound annual growth rate (CAGR) of 18.9%. Factors contributing to its historical growth include a rise in cancer cases, enhanced investment in healthcare infrastructure, greater understanding of targeted treatments, an increase in clinical trial initiatives, and boosted government support for oncology research.
The ribonucleic acid (RNA)-based oncolytic therapy market is poised for substantial expansion in the next few years, with its size expected to reach $4.17 billion by 2029, demonstrating a compound annual growth rate (CAGR) of 18.5%. This projected growth can be attributed to several factors, including the increasing adoption of RNA-based treatments, a heightened focus on immuno-oncology, a rise in biotechnology collaborations, the expansion of advanced manufacturing facilities, and improved access to precision medicine. Significant trends anticipated during this period encompass technological advancements, progress in viral vector design, increased investment in research and development, innovations in delivery systems, and the formulation of combination therapy approaches.
Unlock Your Free Sample Report for Exclusive Market Data:
https://www.thebusinessresearchcompany.com/sample.aspx?id=28321&type=smp
What Are The Top Growth Drivers Impacting The Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market Outlook?
The increasing embrace of personalized medicine is anticipated to fuel the expansion of the RNA-based oncolytic therapy market in the future. Personalized medicine involves medical interventions crafted for unique genetic makeups, leading to better effectiveness and fewer side effects. The uptake of personalized medicine is on the rise as more healthcare providers and organizations acknowledge its capacity to improve patient results via focused therapies and accurate diagnostics. RNA-based oncolytic therapy is vital in cancer treatment by aligning with the rising adoption of personalized medicine to provide targeted and patient-centric treatment methods. As an illustration, in February 2024, the Personalized Medicine Coalition, a US-based advocacy organization for customized medical solutions, reported that the FDA sanctioned 16 novel personalized treatments for rare disease patients in 2023, an increase from 6 in 2022. Consequently, the expanding adoption of personalized medicine is propelling the RNA-based oncolytic therapy market.
What Are The Major Segment Categories Driving The Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market Growth?
The ribonucleic acid (RN)-based oncolytic therapy market covered in this report is segmented as
1) By Therapy Type: Messenger Ribonucleic Acid (mRNA)-Based Oncolytic Therapy, Small Interfering Ribonucleic Acid (siRNA)-Based Oncolytic Therapy, Micro Ribonucleic Acid (miRNA)-Based Oncolytic Therapy, Other Therapy Types
2) By Route Of Administration: Intravenous, Intratumoral, Other Route Of Administrations
3) By Application: Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma, Other Applications
4) By End-User: Hospitals, Cancer Research Institutes, Specialty Clinics, Other End-Users
Subsegment:
1) By Messenger Ribonucleic Acid (mRNA)-Based Oncolytic Therapy: Self-Amplifying mRNA (saRNA), Non-Replicating mRNA, Circular RNA (circRNA)-Based mRNA therapy
2) By Small Interfering Ribonucleic Acid (siRNA)-Based Oncolytic Therapy: Chemically Modified siRNA, Nanoparticle-Delivered siRNA, Conjugated siRNA
3) By Micro Ribonucleic Acid (miRNA)-Based Oncolytic Therapy: miRNA Mimics, miRNA Inhibitors (Antagomirs), miRNA Aponges Or Decoys
4) By Other Therapy Types: Long Non-Coding RNA (lncRNA)-Based Therapies, Short Hairpin RNA (shRNA)-Based Therapies, Aptamer-RNA Based Oncolytic Agents
What Are The Major Trends Driving The Growth Of The Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market?
Major companies operating within the ribonucleic acid (RNA)-based oncolytic therapy market are concentrating on developing technological advancements, such as synthetic messenger RNA (mRNA) technology, to boost tumor-targeting efficiency, improve immune system activation, and achieve more precise and durable outcomes in cancer treatment. Synthetic messenger RNA (mRNA) technology is a biotechnological approach that involves designing and delivering laboratory-made mRNA sequences to guide cells in producing specific therapeutic proteins for treating diseases, including cancer. For instance, in June 2024, CSPC Pharmaceutical Group Limited, a pharmaceutical company based in China, obtained regulatory approval in China to commence clinical trials for SYS6020, its synthetic mRNA-based cancer cell therapy. This development signifies a major progression in the country’s landscape of messenger RNA therapeutics. SYS6020 utilizes mRNA-lipid nanoparticle technology to specifically target and eliminate myeloma cancer cells with minimal adverse effects, while also demonstrating potential applications in addressing certain autoimmune diseases.
Which Industry Leaders Are Driving Innovation Across The Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market?
Major companies operating in the ribonucleic acid (rna)-based oncolytic therapy market are AstraZeneca PLC, Moderna Inc., BioNTech SE, Gritstone Bio Inc., Orna Therapeutics Inc., Strand Therapeutics Inc., Oncolytics Biotech Inc., Anima Biotech Inc., eTheRNA immunotherapies NV, Vyriad Inc., Haya Therapeutics Inc., Virogin Biotech Inc., Providence Therapeutics Holdings Inc., Sirnaomics Inc., Humane Genomics Inc., Replicate Bioscience Inc., Abogen Biosciences Inc., Chimeron Bio Inc., Aro Biotherapeutics Inc., TransCode Therapeutics Inc.
Download The Full Report For Exclusive Market Findings:
Which Region Is Expected To Witness The Fastest Growth In The Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market?
North America was the largest region in the ribonucleic acid (RNA)-based oncolytic therapy market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in ribonucleic acid (RNA)-based oncolytic therapy report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
Request A Customized Version Of The Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market Report:
https://www.thebusinessresearchcompany.com/customise?id=28321&type=smp
Browse Through More Reports Similar to the Global Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market 2025, By The Business Research Company
Ribose Nucleic Acid Rna Based Therapeutics Global Market Report 2025
Oncolytic Virus Therapy Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/oncolytic-virus-therapy-global-market-report
Nucleic Acid Based Gene Therapy Global Market Report 2025
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model